Other Events ·
Context Therapeutics stockholders approve increase in authorized common shares to 300 million
CNTXContext Therapeutics Inc.
On June 24, 2026, Context Therapeutics Inc. stockholders approved an amendment to the company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 to 300,000,000. The company also elected seven directors and ratified CohnReznick LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026. Context Therapeutics Inc. is a biotechnology company that develops therapeutics for the treatment of cancer.